Association between cerebral metabolic and structural abnormalities and cognitive performance in schizophrenia

Psychiatry Research - Neuroimaging

Volumn 173, Issue 2, 2009, Pages 88-93

  Molina, Vicente ^a   Solera, Sara ^b   Sanz, Javier ^b   Sarramea, Fernando ^c   Luque, Rogelio ^c   Rodríguez, Roberto ^b   Jiménez Arriero, Miguel Angel ^b   Palomo, Tomás ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Atrophy; Hypofrontality; Neuropsychology; Prefrontal; Processing speed; Schizophrenia; Working memory

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; BRAIN DISEASE; BRAIN METABOLISM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INTELLIGENCE; LEARNING; MALE; MENTAL CAPACITY; NEUROANATOMY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROBLEM SOLVING; SCHIZOPHRENIA; WORKING MEMORY;

ADULT; COGNITION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 67651124801     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2008.09.009     Document Type: Article

References (32)

1. Alvarez J.A., and Emory E. Executive function and the frontal lobes: a meta-analytic review. Neuropsychological Rehabilitation 16 (2006) 17-42
2. Ashburner J., and Friston K.J. Multimodal image coregistration and partitioning - a unified framework. Neuroimage 6 (1997) 209-217
3. Buchsbaum M.S. Positron emission tomography studies of abnormal glucose metabolism in schizophrenic illness. Clinical Neuroscience 3 (1995) 122-130
4. Callicott J.H., Bertolino A., Mattay V.S., Langheim F.J., Duyn J., Coppola R., Goldberg T.E., and Weinberger D.R. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cerebral Cortex 10 (2000) 1078-1092
5. Cannon T.D., Hennah W., van Erp T.G., Thompson P.M., Lonnqvist J., Huttunen M., Gasperoni T., Tuulio-Henriksson A., Pirkola T., Toga A.W., Kaprio J., Mazziotta J., and Peltonen L. Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Archives of General Psychiatry 62 (2005) 1205-1213
6. Cuesta M.J., and Peralta V. Cognitive disorders in the positive, negative, and disorganization syndromes of schizophrenia. Psychiatry Research 58 (1995) 227-235
7. Cuesta M.J., Peralta V., and Zarzuela A. Illness duration and neuropsychological impairments in schizophrenia. Schizophrenia Research 33 (1998) 141-150
8. Dickinson D., Ramsey M.E., and Gold J.M. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Archives of General Psychiatry 64 (2007) 532-542
9. Fuster J.M. Synopsis of function and dysfunction of the frontal lobe. Acta Psychiatrica Scandinavica. Supplementum 395 (1999) 51-57
10. Goldberg T.E., and Weinberger D.R. The effects of clozapine on neurocognition: an overview. Journal of Clinical Psychiatry 55 (1994) 88-90 (Suppl B)
11. Green M.F., Kern R.S., and Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophrenia Research 72 (2004) 41-51
12. Hollingshead A., and Frederick R. Social stratification and psychiatric disorders. American Sociological Review 18 (1953) 163-189
13. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Research 13 (1987) 261-276
14. Lahti A.C., Holcomb H.H., Weiler M.A., Medoff D.R., Frey K.N., Hardin M., and Tamminga C.A. Clozapine but not haloperidol re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology 29 (2004) 171-178
15. MacDonald III A.W., Carter C.S., Kerns J.G., Ursu S., Barch D.M., Holmes A.J., Stenger V.A., and Cohen J.D. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. American Journal of Psychiatry 162 (2005) 475-484
16. Manoach D.S., Press D.Z., Thangaraj V., Searl M.M., Goff D.C., Halpern E., Saper C.B., and Warach S. Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biological Psychiatry 45 (1999) 1128-1137
17. Mesulam M.M. Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Annals of Neurology 28 (1990) 597-613
18. Molina V., Reig S., Sarramea F., Sanz J., Artaloytia J.F., Luque R., Aragüés M., Pascau J., Benito C., Palomo T., and Desco M. Anatomical and functional brain variables associated to clozapine response in treatment-resistant schizophrenia. Psychiatry Research: Neuroimaging 124 (2003) 153-161
19. Molina V., Gispert J.D., Reig S., Pascau J., Palomo T., Martínez R., and Desco M. Olanzapine-induced cerebral metabolic changes. Relation to symptom changes in schizophrenia. International Clinical Psychopharmacology 20 (2005) 13-18
20. Molina V., Sanz J., Reig S., Martínez R., Sarramea F., Luque R., Benito C., Gispert J.D., Pascau J., and Desco M. Hypofrontality in males with first-episode psychosis. British Journal of Psychiatry 186 (2005) 203-208
21. Molina V., Sarramea F., Sanz J., Benito C., and Palomo T. Prefrontal atrophy in first episodes of schizophrenia associated with limbic hyperactivity. Journal of Psychiatric Research 39 (2005) 117-127
22. Molina V., Sanz J., Sarramea F., Luque R., Benito C., and Palomo T. Dorsolateral prefrontal and superior temporal volume deficits in first episode psychosis that evolve into schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 256 (2006) 106-111
23. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., and Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophrenia Research 72 (2004) 29-39
24. Pfefferbaum A., Lim K.O., Zipursky R.B., Mathalon D.H., Rosenbloom M.J., Lane B., Ha C.N., and Sullivan E.V. Brain gray and white matter volume loss accelerates with aging in chronic alcoholics: a quantitative MRI study. Alcoholism: Clinical and Experimental Research 16 (1992) 1078-1089
25. Rummel C., Hamann J., Kissling W., and Leucht S. New generation antipsychotics for first episode schizophrenia. Cochrane Database of Systematic Reviews (2003) CD004410
26. Shenton M.E., Dickey C.C., Frumin M., and McCarley R.W. A review of MRI findings in schizophrenia. Schizophrenia Research 49 (2001) 1-52
27. Sweeney J.A., Haas G.L., and Li S. Neuropsychological and eye movement abnormalities in first-episode and chronic schizophrenia. Schizophrenia Bulletin 18 (1992) 283-293
28. Wechsler D. Wechsler Adult Intelligence Scale (1999), Ediciones TEA, S.A, Madrid
29. Winterer G., and Weinberger D.R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends in Neurosciences 27 (2004) 683-690
30. Wolf R.C., Vasic N., Hose A., Spitzer M., and Walter H. Changes over time in frontotemporal activation during a working memory task in patients with schizophrenia. Schizophrenia Research 91 (2007) 141-150
31. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64 (2003) 663-667
32. Woods R.P., Mazziotta J.C., and Cherry S.R. MRI-PET registration with automated algorithm. Journal of Computer Assisted Tomography 17 (1993) 536-546